GWENDOLYN DANIEL: Open Payments
NPI 1225789019 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$569 in 11 payments from 5 companies in 2025. Trend: 2023 $640 · 2024 $102 · 2025 $569
Food & beverage: $569
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $187 |
| SK Life Science, Inc. | 2 | $140 |
| Neurocrine BioSciences, Inc. | 2 | $138 |
| ACADIA Pharmaceuticals Inc | 1 | $63 |
| Alpha Cognition USA, Inc. | 1 | $40 |
Products named: REXULTI, INGREZZA, XCOPRI, NUPLAZID, Zunveyl.
Industry payments across TX — which companies pay providers there.
